IL118581A - Optically crosslinked communication system - Google Patents

Optically crosslinked communication system

Info

Publication number
IL118581A
IL118581A IL11858196A IL11858196A IL118581A IL 118581 A IL118581 A IL 118581A IL 11858196 A IL11858196 A IL 11858196A IL 11858196 A IL11858196 A IL 11858196A IL 118581 A IL118581 A IL 118581A
Authority
IL
Israel
Prior art keywords
hif
communication system
hypoxia
purified
optically crosslinked
Prior art date
Application number
IL11858196A
Other languages
English (en)
Other versions
IL118581A0 (en
Original Assignee
Glynn Thomas William
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glynn Thomas William filed Critical Glynn Thomas William
Publication of IL118581A0 publication Critical patent/IL118581A0/xx
Publication of IL118581A publication Critical patent/IL118581A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
IL11858196A 1995-06-06 1996-06-05 Optically crosslinked communication system IL118581A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1

Publications (2)

Publication Number Publication Date
IL118581A0 IL118581A0 (en) 1996-10-16
IL118581A true IL118581A (en) 2000-01-31

Family

ID=23908114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11858196A IL118581A (en) 1995-06-06 1996-06-05 Optically crosslinked communication system

Country Status (9)

Country Link
US (3) US5882914A (enExample)
EP (2) EP0833840B1 (enExample)
JP (2) JPH11507541A (enExample)
AT (1) ATE355299T1 (enExample)
AU (1) AU704384B2 (enExample)
CA (1) CA2222279C (enExample)
DE (1) DE69636936T2 (enExample)
IL (1) IL118581A (enExample)
WO (1) WO1996039426A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU8536998A (en) * 1997-06-10 1998-12-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
ATE293633T1 (de) 1997-08-21 2005-05-15 Quark Biotech Inc Hypoxie-regulierte gene
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
EP1034267A1 (en) * 1997-12-04 2000-09-13 Genzyme Corporation Compositions and methods for inducing gene expression
CA2322843A1 (en) * 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford, Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
AU7748200A (en) * 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
US20030180740A1 (en) * 2000-02-22 2003-09-25 Kingsman Alan John Differential expression screening method
CA2418386A1 (en) * 2000-08-07 2002-02-14 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2447958A1 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
ATE432346T1 (de) * 2001-06-05 2009-06-15 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
US20050222061A1 (en) * 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004042024A2 (en) 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
CA2509494A1 (en) * 2002-12-11 2004-06-24 University Of Massachusetts Method of introducing sirna into adipocytes
JP4546454B2 (ja) 2003-01-28 2010-09-15 レクサーン・コーポレイション Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CA2513398C (en) * 2003-01-31 2013-09-10 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
BRPI0515726A8 (pt) * 2004-11-09 2017-09-12 Santaris Pharma As Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
EP3146982B1 (en) 2006-10-03 2019-08-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
AU2009213203B2 (en) * 2008-02-14 2013-06-27 Lincoln University Methods and compositions comprising Trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CA3106271A1 (en) * 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
CN113403338B (zh) 2014-03-28 2025-07-15 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
WO2021247632A1 (en) * 2020-06-02 2021-12-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer
CN116024263A (zh) * 2022-09-23 2023-04-28 龙岩学院 一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
WO2024211763A1 (en) * 2023-04-05 2024-10-10 The Johns Hopkins University Synthetic mrna encoding hif-1alpha and uses for wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479948B1 (en) * 1989-06-23 1998-08-26 Genentech, Inc. Compositions and methods for the synthesis of natriuretic protein receptor b and methods of use
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
EP0833840A4 (en) 2001-12-19
EP1806357A1 (en) 2007-07-11
IL118581A0 (en) 1996-10-16
US6222018B1 (en) 2001-04-24
CA2222279A1 (en) 1996-12-12
AU704384B2 (en) 1999-04-22
EP0833840A1 (en) 1998-04-08
CA2222279C (en) 2011-02-01
EP0833840B1 (en) 2007-02-28
US5882914A (en) 1999-03-16
DE69636936D1 (de) 2007-04-12
ATE355299T1 (de) 2006-03-15
DE69636936T2 (de) 2007-10-31
AU6332696A (en) 1996-12-24
JP2009077729A (ja) 2009-04-16
WO1996039426A1 (en) 1996-12-12
US6020462A (en) 2000-02-01
JPH11507541A (ja) 1999-07-06

Similar Documents

Publication Publication Date Title
IL118581A0 (en) Optically crosslinked communication system
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
CA2009578A1 (en) Excitatory amino acid receptor antagonists
AU3396597A (en) Combination of acid protease enzymes and acidic buffers and uses thereof
AU1943388A (en) 3-indolepyruvic acid derivatives and pharmaceutical use thereof
EP0945135A3 (en) Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
DE69534468D1 (de) Wachstums-differenzierungsfaktor-11
CA2156024A1 (en) Synthetic excitatory amino acids
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
GR3036691T3 (en) Dna sequences related to isolated fragile x syndrome
AU3009089A (en) Tetrazole excitatory amino acid receptor antagonists
CA2006087A1 (en) Polypeptides isolated from the venom of the spider hololena curta
IL128411A (en) Neuritin, a neurogene
FI880324A0 (fi) Foerfarande foer framstaellning av 4-tiazolidinkarboxylsyraderivat.
AU1795783A (en) New polypeptide from thymus glands
DE68906054D1 (de) Hyperimmunizierte milch gegen bluthochdruck.
CS8708732A2 (en) Method of hv1, hv2, hv3 hirodin forms' one variant production
ATE110742T1 (de) Peptid-verbindungen.
CS346591A3 (en) Complexes comprising s-(+)-phenylalkanoic acids and amino sugars
AU2873789A (en) Heparin - binding brain mitogens
EP0576915A3 (en) Cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
DE68909304D1 (de) Aminosäuren für der Behandung neurodegenerativer Störungen.
AU7011098A (en) Treatment of adverse effects associated with administration of extracellular hemoglobin
EP0235904A3 (en) Treatment of allergy with thymopentin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees